Ucb SA
Belgium · BE0003739530 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Good
- Revenue +17% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Fair
- It earned 11% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 58% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
€6.2B
revenue
22%
operating margin
€1.1B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2020 | Dec 2021 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €5.3B | €5.8B | €5.3B | €6.2B |
| Operating profit | €971M | €1.3B | €604M | €1.3B |
| Net profit to shareholders | €732M | €1.1B | €343M | €1.1B |
| Earnings per share | €3.87 | €5.60 | €1.81 | €5.61 |
| Dividend per share | n/a | n/a | €1.33 | €1.36 |
| Cash from operations | €1.1B | €1.6B | €761M | €1.2B |
| Capital spending | €256M | €282M | €238M | €234M |
| Cash | €1.3B | €1.3B | €861M | €1.6B |
| Total assets | €13.3B | €14.2B | €15.5B | €17.3B |
| Equity | €7.3B | €8.4B | €9.0B | €10.0B |
What they do
In the company's own words, from the annual report.
un leader mondial en biopharmacie spécialisé dans les maladies graves relevant de deux domaines thérapeutiques, à savoir la neurologie etl’immunologie.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.